Is Harrow Health, Inc. (HROW) a Buy, Sell, or Hold?
NASDAQ : HROW
Harrow Health, Inc.
$38.45 USD
-$3.43 (-8.19%)
- Volume
- 872.16K
- Average Volume
- 830.26K
- Market Capitalization
- $1.43B
- P/E Ratio
- -97.96
- Dividend Yield
- 0.00%
- Price Target
- $70.00
- Year High
- $54.85
- Year Low
- $28.54
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.48
Company Overview
NASDAQ
Mark L. Baum
Drug Manufacturers - Specialty & Generic
Healthcare
HROW
373
US
USD
Liquidity Metrics
10.47
2.48
2.30
1.04
0.00
Sales & Valuation
$272.3M
5.33
49.87
100.38
0.38
Profitability
-$0.14
-$5.14M
-5.57%
-4.16%
-33.65%
-3.57%
P/E Metrics
-97.96
0.43
0.43
Analyst Price Target & Rating
$70.00
$88.00
$63.00
1/5
10 Analysts
-45.07%
Financial Health Scores
2.95
4/9
$134.94M
$419.54M
$391.19M
$11.96M
Key Metrics (TTM)
$1.77B
6.58
56.16
2.48
-33.65%
8.55%
-0.96%
0.91%
87 days
Company Executives
| Name | Title |
|---|---|
| Kim Barratt | Chief Talent Officer |
| Francis W. Mullery | President & Chief Executive Officer of Harrow's ImprimisRx Division |
| Brett A. Burrell | Vice President of Legal & Compliance |
| Frank W. Mullery | President & Chief Executive Officer of Harrow's ImprimisRx Division |
| Patrick W. Sullivan | Chief Commercial Officer |
| Mark L. Baum | CEO, Chairman of the Board & Founder |
| Amir W. Shojaei | Chief Scientific Officer |
| Andrew R. Boll | President, Chief Financial Officer & Corporate Secretary |
| Mark A. Mannebach | Head of Regulatory Affairs & Pharmacovigilance |
| Michael D. Biega | Vice President of Investor Relations & Communications |
| Randall E. Pollard | Chief Accounting Officer |
| Vincent Mair | Senior Vice President of Commercial Operations |
| Prashanth S. Annavajjhala | Chief of Staff |
Poll Results
No votes yet today — be the first to share your view!
About Harrow Health, Inc. (NASDAQ:HROW) Stock
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environment ... s; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
2026-07-20 08:00:00
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd.
2026-07-20 07:00:00
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectively, the presentations expand the growing body of clinical and real-world evidence supporting Harrow's retina portfolio and reinforce Harrow's commitment to generating quality evidence that strengthens physician confidence, improves patient experience, and supports long-term product adoption and innovation.
2026-07-01 07:00:00
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 20.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
2026-07-01 07:00:00
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
2026-06-11 11:51:08
Harrow shares gain after relaunching Verkazia in the United States, aiming to improve access to an FDA-approved VKC treatment for pediatric patients.
Harrow Adds Another Piece To Ophthalmology Strategy
2026-06-11 11:42:29
Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children.
2026-06-10 07:00:00
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.
Harrow to Present at William Blair's 46th Annual Growth Stock Conference
2026-05-27 07:00:00
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
Frequently Asked Questions
-
What is the current Harrow Health, Inc. (HROW) stock price?
-
Harrow Health, Inc.(NASDAQ:HROW) stock price is $38.45 in the last trading session. During the trading session, HROW stock reached the peak price of $54.85 while $28.54 was the lowest point it dropped to. The percentage change in HROW stock occurred in the recent session was --8.19% while the dollar amount for the price change in HROW stock was -$3.43.
-
HROW's industry and sector of operation?
-
The NASDAQ listed HROW is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of HROW?
-
Kim Barratt | Chief Talent Officer
Francis W. Mullery | President & Chief Executive Officer of Harrow's ImprimisRx Division
Brett A. Burrell | Vice President of Legal & Compliance
Frank W. Mullery | President & Chief Executive Officer of Harrow's ImprimisRx Division
Patrick W. Sullivan | Chief Commercial Officer -
How many employees does HROW have?
-
Number of HROW employees currently stands at 373. HROW operates from 102 Woodmont Boulevard, Nashville, TN 37205, US.
-
Link for HROW official website?
-
Official Website of HROW is: https://www.harrow.com
-
How do I contact HROW?
-
HROW could be contacted at phone #615 733 4730 and can also be accessed through its website. HROW operates from 102 Woodmont Boulevard, Nashville, TN 37205, US.
-
How many shares of HROW are traded daily?
-
The average number of HROW shares traded daily for last 3 months was 830.26K.
-
What is the market cap of HROW currently?
-
The market value of HROW currently stands at $1.43B with its latest stock price at $38.45